Trump signs law that subjects all biosimilar patent settlements to FTC scrutiny

Trump signs law that subjects all biosimilar patent settlements to FTC scrutiny

Heightened concern over pay-for-delay strategies has driven the legislation at a time when the number of biosimilars being approved is set to rise sharply

Unlock unlimited access to all IAM content